Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cisplatin-Paclitaxel-Gemcitabine in Advanced Bladder Cancer
NCT00006118Phase 2Unknown
- Sponsor
- GERCOR
- Start
- Jul 1999
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of cisplatin, paclitaxel and gemcitabine in bladder cancer, sponsored by GERCOR. Primary endpoints: Efficacy (Response Rate) and Toxicity. Status: unknown.
02
Drugs
cisplatinpaclitaxelgemcitabine
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT00006118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00006118.